Inimmune's CSO, Jay Evans, to Provide Latest Insights on Clinical Programs at the International Precision Vaccine Conference in Rome on October 5-6

 

Inimmune's CSO, Jay Evans, to Provide Latest Insights on Clinical Programs at the International Precision Vaccine Conference in Rome on October 5-6

Inimmune, a prominent biotechnology firm dedicated to pioneering vaccine adjuvants, immunotherapies, and advanced delivery systems, proudly announces the participation of its Chief Scientific and Strategy Officer, Dr. Jay Evans, at the esteemed International Precision Vaccines Conference (IPVC) in Rome, Italy, scheduled for October 5-6, 2023.

IPVC, a gathering of leading experts in vaccinology and immunology hailing from academia, governmental agencies, and the private sector, will focus on Precision Vaccines: Biomarkers of Vaccine Safety and Efficacy in Vulnerable Populations. Dr. Evans expressed enthusiasm about Inimmune's involvement in IPVC and its commitment to contributing to groundbreaking discussions on innovative vaccines and immunotherapeutics.

Inimmune's transformative journey from pre-clinical research to clinical trials commenced in 2023 with the launch of a Phase I clinical trial for a novel treatment targeting seasonal allergic rhinitis. Furthermore, Inimmune anticipates initiating immuno-oncology and vaccine Phase I clinical trials in early 2024. Dr. Evans is slated to deliver a comprehensive update on Inimmune's strides in advancing new vaccine adjuvants and immunotherapy solutions, including a collaborative project with Boston Children's Hospital's Precision Vaccines Program focusing on the development of PVP-037, a small molecule TLR7 agonist.

Vaccine adjuvants, such as those pioneered by Inimmune, play a pivotal role in enhancing the immune response to vaccines and have broader applications in medical domains, including immuno-oncology, allergies, and autoimmunity. Inimmune's unwavering dedication centers on crafting innovative vaccine adjuvants and delivery systems that promise to augment global healthcare, underscored by a rapidly expanding portfolio of pioneering immunotherapeutics.

Dr. Ofer Levy, M.D., Ph.D., Director of the Precision Vaccines Program at Boston Children's Hospital and Co-Organizer of IPVC, expressed gratitude for Inimmune's support in co-sponsoring the IPVC conference and welcomed Dr. Evans. He emphasized the substantial potential of precision adjuvants across various medical indications to prevent and treat diseases in vulnerable populations.

The conference agenda spans two full days, featuring seminars, poster sessions, and interactive forums where recent studies on vaccine safety and immunogenicity relevant to vulnerable populations will be discussed and deliberated. The event is scheduled to take place on October 5-6 at the Parco dei Principi Grand Hotel & Spa in Rome, Italy.

About Inimmune:

Inimmune Corp., headquartered in Missoula, MT, is a privately held biotechnology enterprise with a sharp focus on the discovery and development of groundbreaking immunotherapeutics, adjuvants, and vaccines. Leveraging the remarkable capabilities of the human immune system, Inimmune strives to craft safe and efficacious treatments for conditions spanning allergies, infectious diseases, autoimmunity, and cancer. The company's state-of-the-art laboratories and offices are located within the Montana Technology Enterprise Center (MonTEC) in Missoula, MT, USA.